| Literature DB >> 28561228 |
Thorsten Simon1, Barbara Hero1, Johannes H Schulte2, Hedwig Deubzer2, Patrick Hundsdoerfer2, Dietrich von Schweinitz3, Jörg Fuchs4, Matthias Schmidt5, Vikas Prasad6, Barbara Krug7, Beate Timmermann8, Ivo Leuschner9, Matthias Fischer10, Thorsten Langer11, Kathy Astrahantseff2, Frank Berthold1, Holger Lode12, Angelika Eggert2.
Abstract
The clinical course of neuroblastoma is more heterogeneous than any other malignant disease. Most low-risk patients experience regression after limited or even no chemotherapy. However, more than half of high-risk patients die from disease despite intensive multimodal treatment. Precise patient characterization at diagnosis is key for risk-adapted treatment. The guidelines presented here incorporate results from national and international clinical trials to produce recommendations for diagnosing and treating neuroblastoma patients in German hospitals outside of clinical trials. © Georg Thieme Verlag KG Stuttgart · New York.Entities:
Mesh：
Year: 2017 PMID： 28561228 DOI： 10.1055/s-0043-103086
Source DB: PubMed Journal: Klin Padiatr ISSN： 0300-8630 Impact factor: 1.349